Latest News

Immunomodulators Do Not Affect COVID-19 Vaccine Efficacy


 

TOPLINE:

The results of a recent study suggest that biologics and small molecule inhibitors (SMIs) do not impair the protective effect of COVID-19 vaccine against hospitalization in patients with psoriasis and hidradenitis suppurativa (HS).

METHODOLOGY:

  • It remains unknown whether immunomodulatory therapies impair COVID-19 vaccine efficacy and increase hospitalization rates linked to COVID-19 in patients with inflammatory skin conditions such as psoriasis or HS.
  • Researchers conducted a cross-sectional study using data from the Epic Cosmos database from January 2020 to October 2023, identifying 30,845 patients with psoriasis or HS.
  • Overall, 22,293 patients with documented completion of their primary COVID-19 vaccine series were included in the analysis.
  • Of the vaccinated patients, they compared 7046 patients with psoriasis on SMIs and 2033 with psoriasis or HS on biologics with 13,214 patients who did not receive biologics or SMIs.
  • The primary outcome was the COVID-19 hospitalization rate.
  • Treatment with biologics did not increase COVID-19-related hospitalization rates in vaccinated patients with psoriasis or HS (hospitalization rate, 6.0% for both those taking and those not taking a biologic; P > .99).
  • Similarly, hospitalization rates did not significantly differ between vaccinated patients who received SMIs vs those who did not (7.1% vs 6.0%; P = .0596).

IN PRACTICE:

These findings “encourage dermatologists to continue treating [psoriasis]/HS confidently despite the ongoing COVID-19 pandemic,” the authors concluded.

SOURCE:

The study led by Bella R. Lee from Ohio State University Wexner Medical Center, Columbus, was published online on March 13, 2024, in the Journal of the American Academy of Dermatology.

LIMITATIONS:

Multivariable adjustments could not be performed in this study due to unavailability of individual-level data, and hospital admissions that occurred outside the Epic system were not captured.

DISCLOSURES:

The study did not receive any funding. All authors declared no conflicts of interest.

A version of this article appeared on Medscape.com.

Recommended Reading

Q&A: What to know about the new BA 2.86 COVID variant
MDedge Dermatology
Effect of COVID-19 Vaccination on Disease Severity in Patients With Stable Plaque Psoriasis: A Cross-sectional Study
MDedge Dermatology
New Moderna vaccine to work against recent COVID variant
MDedge Dermatology
More evidence shows COVID-19’s link to risk for autoimmune disease
MDedge Dermatology
Impact of the COVID-19 Pandemic on Care for Patients With Atopic Dermatitis
MDedge Dermatology
Reactive Angioendotheliomatosis Following Ad26.COV2.S Vaccination
MDedge Dermatology
Analysis Finds Risk of Alopecia Areata After COVID-19 Infection
MDedge Dermatology
Five Bold Predictions for Long COVID in 2024
MDedge Dermatology
Mixing Paxlovid With Specific Immunosuppressants Risks Serious Adverse Reactions
MDedge Dermatology
Dermatologic Reactions Following COVID-19 Vaccination: A Case Series
MDedge Dermatology